2 Chlorodeoxyadenosine Activity and Cross Resistance Patterns in Primary Cultures of Human Hematologic Neoplasms

Overview

Journal Br J Cancer

Specialty Oncology

Date 1993 Jan 1

PMID 8094002

Citations 7

Authors

R A Nagourney

S S Evans

J C Messenger

Y Z Su

L M Weisenthal

Affiliations

Soon will be listed here.

Abstract

2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside. The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class. The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may help to elucidate drug activities and mechanisms of action.

Citing Articles

Precision medicine for cancer with next-generation functional diagnostics.

Friedman A, Letai A, Fisher D, Flaherty K Nat Rev Cancer. 2015; 15(12):747-56.

PMID: 26536825 PMC: 4970460. DOI: 10.1038/nrc4015.

Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Cai B, Wang S, Huang J, Lee C, Gao C, Liu B Am J Transl Res. 2013; 5(1):36-46.

PMID: 23390564 PMC: 3560475.

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

Ma J, Wang S, Zhao M, Deng X, Lee C, Yu X BMC Cancer. 2011; 11:255.

PMID: 21679466 PMC: 3141773. DOI: 10.1186/1471-2407-11-255.

Ex vivo programmed cell death and the prediction of response to chemotherapy.

Nagourney R Curr Treat Options Oncol. 2006; 7(2):103-10.

PMID: 16455021 DOI: 10.1007/s11864-006-0045-2.

Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP.

Bosanquet A, Burlton A, Bell P, Harris A Br J Cancer. 1997; 76(4):511-8.

PMID: 9275029 PMC: 2227987. DOI: 10.1038/bjc.1997.417.

References

Piro L, Carrera C, Beutler E, Carson D . 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988; 72(3):1069-73. View

Kay A, Saven A, Carrera C, Carson D, Thurston D, Beutler E . 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992; 10(3):371-7. DOI: 10.1200/JCO.1992.10.3.371. View

Griffig J, Koob R, Blakley R . Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989; 49(24 Pt 1):6923-8. View

Tanabe K, Hiraoka W, Kuwabara M, Sato F, Matsuda A, Ueda T . Induction of DNA double-strand breaks in Chinese hamster V79 cells by 2-chlorodeoxyadenosine. Chem Biol Interact. 1989; 71(2-3):167-75. DOI: 10.1016/0009-2797(89)90032-x. View

Gazdar A, Steinberg S, RUSSELL E, Linnoila R, Oie H, Ghosh B . Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990; 82(2):117-24. DOI: 10.1093/jnci/82.2.117. View

Carrera C, Yamanaka H, Piro L, Lotz M, Carson D . Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv Exp Med Biol. 1989; 253B:219-25. DOI: 10.1007/978-1-4684-5676-9_33. View

Tidefelt U, Sundman-Engberg B, Rhedin A, Paul C . In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol. 1989; 43(5):374-84. DOI: 10.1111/j.1600-0609.1989.tb00323.x. View

Hentosh P, Koob R, Blakley R . Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem. 1990; 265(7):4033-40. View

Piro L, Carrera C, Carson D, Beutler E . Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990; 322(16):1117-21. DOI: 10.1056/NEJM199004193221605. View

10.

Lathan B, von Tettau M, Verpoort K, Diehl V . Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus. 1990; 33:295-8. DOI: 10.1007/978-3-642-74643-7_53. View

11.

Smulson M, Schein P, Mullins Jr D, Sudhakar S . A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 1977; 37(9):3006-12. View

12.

Berger N, Sikorski G, Petzold S, Kurohara K . Association of poly(adenosine diphosphoribose) synthesis with DNA damage and repair in normal human lymphocytes. J Clin Invest. 1979; 63(6):1164-71. PMC: 372064. DOI: 10.1172/JCI109410. View

13.

Carson D, Wasson D, Kaye J, Ullman B, Martin Jr D, ROBINS R . Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980; 77(11):6865-9. PMC: 350391. DOI: 10.1073/pnas.77.11.6865. View

14.

Weisenthal L, Marsden J, Dill P, Macaluso C . A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983; 43(2):749-57. View

15.

Bosanquet A . Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents. Cancer Chemother Pharmacol. 1985; 14(2):83-95. DOI: 10.1007/BF00434343. View

16.

Seto S, Carrera C, Kubota M, Wasson D, Carson D . Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985; 75(2):377-83. PMC: 423498. DOI: 10.1172/JCI111710. View

17.

Bird M, Bosanquet A, Forskitt S, Gilby E . Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res. 1986; 10(4):445-9. DOI: 10.1016/0145-2126(86)90075-5. View

18.

Pemble L, Lihou M, Blakley R, Jamieson G, Smith P . Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells. Cancer Chemother Pharmacol. 1987; 20(2):155-61. DOI: 10.1007/BF00253971. View

19.

Carson D, Wasson D, Taetle R, Yu A . Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983; 62(4):737-43. View

20.

Carson D, Wasson D, Beutler E . Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Natl Acad Sci U S A. 1984; 81(7):2232-6. PMC: 345472. DOI: 10.1073/pnas.81.7.2232. View